Compare Organon & Co. Common Stock (OGN) vs Sempra Energy (SRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Sempra Energy — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Sempra Energy trades at $82.38 (market cap $53.86B). The key difference: Sempra Energy is far larger — about 14.9× Organon & Co. Common Stock's market cap, and Sempra Energy pays the higher dividend (3.19%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Sempra Energy for 9 Days on average.
| OGN | SRE | |
|---|---|---|
Market Cap | $3.62B | $53.86B |
Volume | 2,892,999 | 2,605,713 |
Sector | Health | Utilities |
52-Week High | $13.81 | $99.75 |
52-Week Low | $5.70 | $76.90 |
Typical Hold Time | 0 Days | 9 Days |
Enterprise Value | $11.04B | $90.50B |
Dividend Yield | 0.58% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Sempra Energy (SRE) trades at $82.37, up 0.6% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages and oscillators. The company reported strong Q2 2026 earnings that beat expectations, with a net income margin of 16.83% and robust cash flow from operations of $5.4 billion in 2026. Recent developments include a 20-year LNG supply agreement with Petrobras and the opening of SoCalGas' new headquarters, signaling growth initiatives.
The outlook for SRE is positive, supported by analyst consensus with an 80.77% buy rating and a price target of $97.25, implying significant upside. Key opportunities include EPS growth guidance of 7–9% and strategic investments in Texas and LNG. Risks involve high capital expenditures, regulatory exposure, and interest rate sensitivity. The stock's current valuation at a P/E of 23.88 requires continued execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Sempra Energy
Sempra is an energy infrastructure company with regulated utility and energy network businesses. Its operations include electric and gas utilities as well as energy infrastructure in North America.
Read more on SRE →
